Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Topical and Systemic JAK Inhibitors in Dermatology
Farzan Solimani, Katharina Meier, Kamran Ghoreschi
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 242

Showing 1-25 of 242 citing articles:

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 394
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1409-1431
Open Access | Times Cited: 239
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 1, pp. 71-87
Open Access | Times Cited: 228
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Cheng Zhou, Xiangqian Li, Chen Wang, et al.
Clinical Reviews in Allergy & Immunology (2021) Vol. 61, Iss. 3, pp. 403-423
Closed Access | Times Cited: 217
New Treatment Addressing the Pathogenesis of Psoriasis
Michio Tokuyama, Tomotaka Mabuchi
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7488-7488
Open Access | Times Cited: 215
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
Carlo Alberto Maronese, Matthew A. Pimentel, May M. Li, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 5, pp. 615-634
Open Access | Times Cited: 141
Current Concepts of Psoriasis Immunopathogenesis
Marijana Vičić, Marija Kaštelan, Ines Brajac, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11574-11574
Open Access | Times Cited: 104
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 10, pp. 2616-2628.e7
Closed Access | Times Cited: 54
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 46
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial
Stephan Weidinger, Thomas Bieber, Michael J. Cork, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 5, pp. 531-539
Open Access | Times Cited: 45
Immune response patterns in non‐communicable inflammatory skin diseases
K. Eyerich, S. Eyerich
Journal of the European Academy of Dermatology and Venereology (2017) Vol. 32, Iss. 5, pp. 692-703
Open Access | Times Cited: 141
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Yiming Luo, Madison Alexander, Massimo Gadina, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 911-925
Open Access | Times Cited: 86
Molecular and Cellular Mechanisms of Itch in Psoriasis
Eriko Komiya, Mitsutoshi Tominaga, Yayoi Kamata, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8406-8406
Open Access | Times Cited: 74
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Vivian Y. Shi, Tina Bhutani, Luz Fonacier, et al.
Journal of the American Academy of Dermatology (2022) Vol. 87, Iss. 2, pp. 351-358
Open Access | Times Cited: 66
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studies*
Afsáneh Alavi, Iltefat Hamzavi, Kurt Brown, et al.
British Journal of Dermatology (2022) Vol. 186, Iss. 5, pp. 803-813
Open Access | Times Cited: 65
Lichen planus – a clinical guide
Farzan Solimani, Stephan Forchhammer, Alexandra Schloegl, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 6, pp. 864-882
Open Access | Times Cited: 64
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
Kerry-Ann L Dillon
Clinical Cosmetic and Investigational Dermatology (2021) Vol. Volume 14, pp. 691-714
Open Access | Times Cited: 61
Janus kinase inhibitors in dermatology: Part I. A comprehensive review
Stephanie Chapman, Michael Kwa, Linda Stein Gold, et al.
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 2, pp. 406-413
Closed Access | Times Cited: 61
Alopecia areata – Current understanding and management
Dimitra Aikaterini Lintzeri, Andria Constantinou, Kathrin Hillmann, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2022) Vol. 20, Iss. 1, pp. 59-90
Open Access | Times Cited: 59
Therapeutic strategies for oral lichen planus: State of the art and new insights
Dario Didona, Raffaele Dante Caposiena, Antonio Manuel Sequeira Santos, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 59
Psoriasis: Recent progress in molecular‐targeted therapies
Masaru Honma, Kei Hayashi
The Journal of Dermatology (2021) Vol. 48, Iss. 6, pp. 761-777
Closed Access | Times Cited: 57
Janus kinase inhibitors in dermatology: Part II. A comprehensive review
Stephanie Chapman, Linda Stein Gold, Henry W. Lim
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 2, pp. 414-422
Open Access | Times Cited: 57
From Emollients to Biologicals: Targeting Atopic Dermatitis
Lorenzo Salvati, Lorenzo Cosmi, Francesco Annunziato
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10381-10381
Open Access | Times Cited: 56
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies
Stephanie L Schell, Zhaoyuan Cong, Mackenzie L. Sennett, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 3, pp. 407-419
Closed Access | Times Cited: 39
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 801-801
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top